|
|
Gene Symbol |
CPB2 |
|
Aliases |
CPU, PCPB, TAFI |
|
Entrez Gene ID |
|
|
Gene Name |
Carboxypeptidase B2 |
|
Chromosomal Location |
13q14.13 |
|
HGNC ID |
|
|
Summary |
Carboxypeptidases are enzymes that hydrolyze C-terminal peptide bonds. The carboxypeptidase family includes metallo-, serine, and cysteine carboxypeptidases. According to their substrate specificity, these enzymes are referred to as carboxypeptidase A (cleaving aliphatic residues) or carboxypeptidase B (cleaving basic amino residues). The protein encoded by this gene is activated by trypsin and acts on carboxypeptidase B substrates. After thrombin activation, the mature protein downregulates fibrinolysis. Polymorphisms have been described for this gene and its promoter region. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jun 2013]
|
|
RefSeq DNA |
|
|
RefSeq mRNA |
|
|
e!Ensembl
|
Protein Information |
|
Protein Name |
Carboxypeptidase B2, carboxypeptidase B-like protein, carboxypeptidase B2 (plasma), carboxypeptidase B2 (plasma, carboxypeptidase U), carboxypeptidase R, thrombin-activable fibrinolysis inhibitor, thrombin-activatable fibrinolysis inhibitor |
|
Function |
Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin. |
|
|
|
|
|
UniProt |
|
|
PDB |
|
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000353444 |
P61020 |
P61020 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Endocrine System Diseases |
PCOS |
|
Nutritional and Metabolic Diseases |
Obesity |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
|
Cardiovascular diseases |
|
|
Related
|
|
|
|
Lipoproteins,(PAI-1,fibrinogen concentration, thrombomodulin, thrombin-antithrombin (TAT) complexes,Antithrombin III (AT III) and activated protein C |
|
|
|
Related
|
|
This study showed that plasma levels of TAFI, PAI-1, D-dimer, AT III and thrombomodulin were significantly increased in women with PCOS compared with age- and BMI-matched controls. |
|
DHEAS,E(2) |
Obesity,cardiovascular diseases and insulin resistance |
|
Rotterdam criteria |
Related
|
|
Young overweight or obese women with PCOS have increased plasma thrombin-activatable fibrinolysis inhibitor levels |
|
|
|
|